Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
CRO Sygnature Discovery plans to send 60 UK staffers packing
(2d)
Corcept submitted lead asset for approval despite FDA flagging risk of ‘significant review issues’
(2d)
Moderna's latest CMO steps down after barely a year
(2d)
Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech
(2d)
Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program
(2d)
AstraZeneca returns to China’s CSPC for $4.7B obesity deal
(2d)
Moderna offloads late-stage rare disease drug to Recordati for $50M upfront
(2d)
Chutes & Ladders—Cardiff churns C-suite to advance cancer candidate
(3d)
Inside Henlius’ global growth strategy
(3d)
Formation Bio’s China shopping spree continues with $500M biobucks autoimmune pact
(3d)
Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials
(3d)
Sanofi abandons attempt to develop next-gen mRNA seasonal flu vaccine
(3d)
Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout
(3d)
AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities
(3d)
Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor
(3d)
Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales
(3d)
Repertoire adds Lilly to range of Big Pharma partners in autoimmune deal worth up to $2.69B
(4d)
Eikon sets $274M goal for upcoming stock market debut
(4d)
The new rules of biopharma M&A: 4 trends driving dealmaking this year
(4d)
Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M
(4d)
BioPharma Dive
Amgen gives up on its once-prized eczema drug
(2d)
AstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC
(2d)
Politicization runs deeper than ever at FDA, risking long-term impacts
(2d)
The biopharma industry outlook on 2026: Optimism and tension
(3d)
Sanofi expects vaccine sales growth to dip amid ‘challenging environment’
(3d)
AstraZeneca strengthens China ties with planned $15B investment
(3d)
Moderna holds a ‘garage sale’; Roche defends obesity drug data
(3d)
Tenpoint wins FDA nod for combination presbyopia eye drop
(3d)
Lilly bets on Seamless, delving further into genetic medicine for hearing loss
(4d)
Drugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts
(4d)
Halozyme buys a biotech startup; Cytokinetics launches heart drug
(4d)
Regenxbio gene therapy trials suspended by FDA over safety worries
(4d)
FDA lifts hold on an Intellia CRISPR drug trial
(5d)
Roche, trailing in obesity, showcases new data for GLP-1 shot
(5d)
An immune drug developer raises $50M to finance its eczema drug testing
(5d)
China’s edge in early-stage drugmaking ‘likely to persist,’ Pitchbook says
(6d)
Sarepta, battling slowing sales, claims Duchenne gene therapy’s impact grows with time
(6d)
Biotech investor Cormorant secures $150M for another SPAC deal
(6d)
Express Scripts considering settlement in FTC insulin price lawsuit
(6d)
The formula for biotech success in 2026: Confidence, resilience and funding
(6d)
Endpoints News
Big Pharma earnings kick off; Third-round IRA drugs selected; Hengrui’s trailblazing moment; and more
(1d)
FDA says it explained issues early on for Corcept's rejected Cushing's syndrome drug
(2d)
Bitterroot reverts to preclinical biotech in CD47 as CEO leaves
(2d)
CHMP opposes Lilly’s Mounjaro in heart failure, backs Novo’s Kayshild
(2d)
Ultragenyx resubmits gene therapy for rare neuro disease to FDA
(2d)
Quince's steroid therapy for rare disease fails, shares tank
(2d)
Moderna licenses Phase 3 asset to Recordati; ProMIS' private placement
(2d)
Amgen ends partnership with Kyowa Kirin on immunology drug, despite Phase 3 wins
(2d)
Lilly unveils $3.5B factory that will make retatrutide and other obesity drugs
(2d)
Janux hires CMO after T cell engager deal with Bristol Myers; A batch of appointments at Lexeo
(2d)
Reed Jobs' cancer biotech investment firm Yosemite eyes $350M fund
(2d)
AstraZeneca pays $1.2B for CSPC's long-acting obesity drugs
(2d)
Takeda 'anticipated' Medicare negotiations for top seller Entyvio
(3d)
Takeda is ‘not in favor’ of Trump’s MFN deals, CEO-designate says
(3d)
Takeda is ‘not in favor’ of MFN, CEO-designate says
(3d)
White House postpones planned TrumpRx launch event
(3d)
Sanofi vows to stay committed to vaccines as portfolio takes a hit
(3d)
The disrupted fate of pharmacy startups
(3d)
Sanofi's pipeline cuts; Breakthru Medicine raises $60M
(3d)
Summit says FDA will decide to approve its cancer drug by November
(3d)
BioSpace
Despite Wide Support for Rare Disease, Voucher Program Caught Up in Senate's ICE Fight
(2d)
FDA’s Multiple Myeloma Guidance Highlights Decade of Success
(2d)
TrumpRx Delayed Amid Potential Anti-Kickback Concerns
(2d)
Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M
(2d)
AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront
(2d)
Sanofi Moves Away From mRNA Flu Vaccine as CEO Projects Confidence
(2d)
Summit’s Potential Keytruda Rival Gets November FDA Decision Date
(2d)
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
(3d)
AstraZeneca Pledges $15B More in Chinese Investments for Cell Therapies, Radiopharma
(3d)
Sanofi Suffers Another Sales Dip For 'Gift to Public Health' Vaccines
(3d)
Roche Plans to Go Toe-to-Toe With Novo, Lilly in Obesity
(3d)
Lilly Establishes up to $2.7B Repertoire Deal in Second Immune Play of 2026
(3d)
Biotech’s New Cycle, JPM Deal Hype and Where Alpha Still Hides
(3d)
10 Companies Hiring IT Professionals Now
(3d)
Hiring Plans Show Promise for Biopharma Job Seekers: BioSpace Report
(3d)
REGENXBIO Delay Could Put Denali in Pole Position for Hunter Syndrome Approval
(4d)
BMS-Partnered Cellares Raises $257M for Cell Therapy Manufacturing Expansion
(4d)
J&J’s Darzalex Faspro Notches Another Multiple Myeloma Indication, Pushing Into Frontline
(4d)
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
(4d)
Cardiff Craters Amid Executive Exits, Mixed Mid-Stage Data
(4d)
STAT News
STAT readers on shared decision-making, prostate cancer screening, and more
(1d)
Up and down the ladder: The latest comings and goings
(2d)
New rule would force PBMs to disclose drug rebates and other fees
(2d)
Newsom files a civil rights complaint against CMS’ Oz in latest feud with the Trump administration
(2d)
AstraZeneca looks to China for obesity drug candidates
(2d)
We’re reading about TrumpRx questions, drugmakers lowering some prices, and more
(2d)
NIH announces first strategic plan for disability health research
(2d)
7 pediatric bioethicists: Proposed ban on Medicaid funding for hospitals providing gender-affirming care for minors is deeply unethical
(2d)
The food nationalism of the new dietary guidelines
(2d)
Tenuous biomedical funding has put first-year Ph.D. students in a bind
(2d)
How direct-to-consumer health tests could impact insurance, mortgages, and employment
(2d)
Trump’s addiction initiative brings bold rhetoric but few details
(3d)
Trump’s latest deal: $600 million of tech company discounts to help implement Medicaid work requirements
(3d)
The high stakes for Huntington’s patients
(3d)
Senators raise concerns about TrumpRx in letter to HHS watchdog
(3d)
Genes influence human lifespan far more than thought, new study suggests
(3d)
States are the next vaccine battleground
(3d)
Nine states challenge federal mandate that disabled people receive care in community
(3d)
Oz, other officials meet with key senators to push Trump’s ideas for lower drug prices
(3d)
Lilly, Repertoire strike $2 billion autoimmune alliance
(3d)
BioPharma Trend
How Digital Health Technologies are Reshaping Clinical Development
(9h)
This AI Ready Single Molecule Proteomics $1.6M Grant Targets Parkinson’s Alpha Synuclein
(3d)
Eli Lilly Strikes Up to $1.1B Gene Editing Deal with German Startup
(4d)
FDA Greenlights First Human Trial of Epigenetic ‘Rejuvenation’ Therapy for Vision Loss
(4d)
This Company Claims World-First AI Models For Programmable Gene Insertion
(4d)
Antheia Adds $24M in Series C Extension to Expand U.S. Biosynthetic Drug Manufacturing
(5d)
In Another Major R&D Deal, Insilico Taps Chinese Pharma for AI-Designed Cardiometabolic Drugs
(5d)
Insilico Medicine Launches AI Gym for LLMs and Secures FDA Clearance for AI-Designed NLRP3 Inhibitor
(6d)
Neurotech Trends in 2025: When Use Cases Started Driving Design
(1w)
“ChatGPT for Doctors” Raises $250M Series D at $12B Valuation
(1w)
Tempus Launches Paige Predict Following $81M Paige AI Acquisition
(1w)
Scribe to Start First Human Trial of One-Time CRISPR Therapy for Cardiovascular Disease
(1w)
BioAge to Begin Mid-2026 Trial of Oral NLRP3 Inhibitor in Diabetic Macular Edema
(2w)
In a $66M Deal, Insilico Medicine and Hygtia Will Develop an AI-Designed Brain-Penetrant NLRP3 Inhibitor for CNS Diseases
(2w)
Isomorphic Labs and Johnson & Johnson Partner on AI-Driven, Multi-Modality Drug Discovery
(2w)
In One Day, AI Drug Discovery Touched Big Pharma, the Clinic, Regulators, and Public Science
(2w)
OpenAI Backs Ultrasound-Based Brain-Computer Interface Startup With $252M Seed Round
(2w)
Illumina Launches Billion-Cell CRISPR Dataset for AI-Driven Drug Discovery, Built with AstraZeneca, Merck, and Lilly
(2w)
VantAI Renames, Raises $80M to Scale AI Platform for Proximity-Based Drug Discovery
(2w)
Insilico Deploys its Chemistry Foundation Model on Microsoft Discovery Platform
(2w)
Drug Channels
From Cost Center to Insights Center: How Patient Support Will Go Beyond the Call in 2026
(2d)
Drug Channels News Roundup, January 2026: Cuban vs. Optum, McKesson’s Biosimilar Play, States vs. Accumulators, 340B Windfalls, and Ozempic Ads
(5d)
New Drug Launches in a Self-Pay World: Why Access Strategy Matters as Much as Innovation
(1w)
The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs
(1w)
The Net Pricing Revolution in the Drug Channel: What’s Deflating the Gross-to-Net Bubble
(3w)
NEW: The Drug Channels 2026 Video Webinar Series
(3w)
Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different
(3w)
U.S. Brand-Name Drug Prices Fell in 2025 as the Net Pricing Drug Channel Emerges
(4w)
Drug Channels Leadership Forum 2026: Request an Invitation Before It’s Too Late!
(4w)
Drug Channels News Roundup, December 2025: The Net Pricing Drug Channel (#NPDC) Era, LillyDirect, My $0.02 on New MFPs, PBMs in Medicaid—and DCLF 2026
(1mo)
340B Hit $81 Billion in 2024: Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth (VIDEO)
(1mo)
340B Hit $81 Billion in 2024 (+23%): Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth
(1mo)
Gross-to-Net Bubble Hits $356B in 2024—But Growth Slows to 10-Year Low (rerun)
(1mo)
The Future of Buy-and-Bill Market Access: Five Drivers of Wholesalers’ Vertical Integration with Physician Practices (rerun)
(1mo)
Who Will Pay for Prescription Drugs in 2033: DCI’s Takeaways from the Latest Government Forecasts (rerun)
(1mo)
Follow the 340B Dollar: Senator Cassidy Exposes How CVS Health and Walgreens Profit as 340B Contract Pharmacies (rerun)
(1mo)
How Large PBMs Make Money Today: A 2025 Drug Channels Update (rerun)
(1mo)
Closing the Specialty Access Gap: How GoodRx Turns Intent Into Therapy Starts
(2mo)
List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs
(2mo)
The Hidden Burdens of Cancer Care: When Insurers Override Doctors
(2mo)
European Biotechnology Magazine
Sanofi ends 2025 on a high, but trims R&D priorities
(2d)
CDMOs dominate the headlines – and Lonza delivers a clear message of strength
(2d)
Vetter: a multi-million-euro investment for new CDMO facility boost for Saarland/Germany
(2d)
After a turbulent phase: a new milestone from Takeda for Heidelberg Pharma
(3d)
Tenpoint wins FDA approval for presbyopia eye drop and raises $235 million
(3d)
Roche: strong growth in all world regions and a full pipeline in late stage
(3d)
Sensorion raised €60M backed by €20M from Sanofi to advance gene therapies for hearing loss
(4d)
China again: Boehringer turns to Shanghai for IBD bispecific
(4d)
Dresden biotech Seamless lands up to $1.1B Eli Lilly deal for gene therapy hearing loss
(4d)
From cell therapy to combat rifles: Genenta bets its future on becoming Italy’s national-security dealmaker
(5d)
UK and US venture firm Epidarex Capital announced first close fund of $145M to build life sciences start-ups
(5d)
After decades in biotech, Gimv draws a line under new life sciences deals
(5d)
For €170 million: Vienna gives AI and life sciences a new home
(5d)
Genmab pauses enrollment in early ADC trial acquired from ProfoundBio
(6d)
UK retains Europe’s top biotech VC spot despite 2025 slowdown
(1w)
London-based Ellipses licenses another oncologic asset from Chinese pharma
(1w)
Board reshuffle at Rentschler
(1w)
IO Biotech weighs strategic options months after FDA advises against melanoma vaccine filing
(1w)
Oxford-based cancer vaccine company Infinitopes closes $35 million seed round
(2w)
A changing playing field: Observations of the 2026 JP Morgan Healthcare Conference from a European perspective
(2w)
Drug Hunter
lanifibranor (IVA-337)
(2d)
2025 Novel Large Molecule FDA Drug Approvals
(3d)
ADCs With Topoisomerase I Inhibitor Payloads Are Challenging Standards of Care in Oncology
(4d)
December 2025 Patent Highlights
(5d)
Hepatotoxicity Headaches: One of the Hardest Risks to De-Risk
(6d)
Section 3: Ligand Binding Basics
(6d)
2025 Molecules of the Year: Nominate!
(1w)
December 2025
(1w)
2025 Novel Small Molecule FDA Drug Approvals
(1w)
ziftomenib
(2w)
delgocitinib
(2w)
acoltremon (AR-15512)
(2w)
NXI / University of Basel: BRD3-Selective Modulators of the Coronin 1 Pathway
(3w)
treosulfan (NSC 39069)
(3w)
“µMAP”ping the Way to a Better Understanding of Biomolecular Interactions
(3w)
camizestrant
(3w)
Top 10 Most Popular Drug Hunter Resources of 2025
(3w)
A New Approach to Drugging MYC: The Application of Translation-Inhibiting Interdictors To MYC-Driven Malignancies
(4w)
Top 10 Most Popular Drug Hunter Reviews of 2025
(4w)
Blocking the IgG Highway: FcRn Biology, Approved Agents, and the Small-Molecule Horizon
(4w)
Labiotech.EU
Johnson & Johnson’s pipeline strategy: What does 2026 have in store for the big pharma?
(2d)
Building a smart oncology pipeline with Cumulus Oncology
(2d)
U.K. biotech ends on a high note in 2025 despite plummeting investments, report reveals
(4d)
U.K. biotech ends on a high note in 2025 despite plummeting investments, report reveals
(4d)
Seven Italian biotechs to know about in 2026
(4d)
How the University of North Carolina at Chapel Hill is enhancing RNAi potency with its new technology
(5d)
A clearer path to relief: sinusitis treatments on the way
(6d)
What does 2026 hold for the biotech industry?
(1w)
Top 5 trends that will drive biopharma in the next decade with Tim Opler
(1w)
Could CRISPR really cure these diseases?
(2w)
Hepatitis B: Are we edging closer to a cure?
(2w)
From science to scale: building biotech companies via milestone leadership
(2w)
Curing ALS? Ten companies developing new treatments in 2026
(2w)
JPM 2026: what’s the outlook like this year?
(2w)
Labiotech’s 15 biopharma companies to watch in 2026
(2w)
The AbbVie strategy, a company at an inflection point
(3w)
Seven biotech companies to know in the Netherlands
(3w)
14 biotech podcasts to tune into in 2026
(3w)
The biggest biotech funding rounds in December 2025
(3w)
M Ventures: pharma CVC and biotech innovation in 2026
(3w)
Bio IT World
Eli Lilly Gears Up for a Busy Year with a Diversified Pipeline
(4d)
Follow the Money: Helicon Peptide Development, Next-Gen Obesity Metabolic Disease Therapies, Cell Stress Sensing Platform
(5d)
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
(6d)
Dealmakers Predict Banner Year as Biopharma M&A Momentum Builds
(1w)
Improved Drug Safety Needs Better Data Before AI
(1w)
AI in Pharma: Progress Made, But Data Challenges Persist
(2w)
10x Genomics Positions Spatial Biology as Center Stage as AI Fuels New Wave of Customer Demand
(3w)
Illumina at JPM 2026: Strong Q4, Clinical Growth, and BioInsight Launch
(3w)
PacBio at JPM 2026: Clinical Momentum and SPRQ-Nx Economics
(3w)
Oxford Nanopore at JPM 2026: Passing the Baton on a 20-Year Journey
(3w)
NVIDIA Bets Big on AI-Driven Drug Discovery, Physical AI, and a $1 Billion Eli Lilly Partnership
(3w)
TechBio Survey Shows a Mixed Industry Outlook, Claude Gaining Ground, More Machine Learning
(3w)
Systems Biology Map for Advancing the Translation of Extracellular Vesicles
(4w)
Insilico Medicine’s IPO, Servier Pharma Deal
(4w)
Trendspotting: Artificial Intelligence, Impact of Global Policies, Data Harmonization
(4w)
Top Stories of 2025: AI for Research, Innovative Practices, Digital Twins
(1mo)
Follow the Money: Molecular Glue Degrader, Physical AI Scientists, TNF Programs
(1mo)
Thermo Fisher’s New Devices, LabGenius, Sanofi Collaboration, Singapore-MIT Alliance Launches New Project
(1mo)
Scientists Discover Allergy-Triggering Role of Peptide in the Gut
(1mo)
Caris Life Sciences, Genentech Announce Oncology Collaboration Worth $1.1 Billion
(1mo)
GEN News
StockWatch: C-Suite Shakeup, Phase III Plans Jolt Cardiff Investors
(10h)
Intranasal Bird Flu Vaccine Protects Against Highly Pathogenic Strains in Rodents
(14h)
Gut Microbes Shape Cancer Growth and Immunity Through Asparagine Metabolism
(2d)
Complex DNA Written at Scale, Genyro Licenses Caltech’s Sidewinder
(2d)
Ex-CEO Behind Bars, 10x’s Clinical Ambitions, Pharma’s AI Gambit
(2d)
Mosaic’s Nanoneedle Granted Advanced Manufacturing Technology Designation for Gene Therapy Products
(2d)
Twenty-Two Genes Could Hike Risk for Long-Term Health Issues After Epstein-Barr Infection
(2d)
DNA-Protein Crosslinks Drive Inflammation Linked to Early Aging
(3d)
Hippocampal Replay Persists but Loses Structure in Alzheimer’s Model
(3d)
Immunotherapy Reduces Plaque in Mouse Arteries, Suggesting Coronary Disease Intervention
(3d)
DeepMind’s AlphaGenome Predicts Genetic Variation Function, Including Disease
(3d)
Barbados Government and BioMed X Partner to Improve AI-Based Early Diabetic Kidney Disease Modeling
(3d)
Brain Organoids Map How Distinct Autism Mutations Converge in Early Development
(4d)
How IFN Signaling Tunes Macrophage Mitochondria in Inflammation Resolution
(4d)
No Pain, No Gain: Insilico ‘Gym’ Gets AI Models Into Shape
(4d)
Nautilus, Weill Cornell Team Up to Apply Single Molecule Proteomics Tech to Parkinson’s
(4d)
Glucose Monitoring with Novel Reusable Sensor
(4d)
pH Denaturation of dsRNA for mRNA Purification
(4d)
Permittivity Provides an In-line Cell Health Early-warning System
(4d)
Rethinking Vaccine Production Platforms for Future Pandemics
(4d)
Cure Today
What MRD Testing Can Mean for Patients With Breast Cancer and Survivors
(9h)
A Patients Navigation Guide to Stage 2 Clear Cell Renal Cell Carcinoma
(13h)
Smoldering Multiple Myeloma: An Overview for Newly Diagnosed Patients
(1d)
Lung Carcinoid Tumors: Diagnosis, Staging and Treatment Options
(1d)
Key GI Cancer Advances from the 2026 ASCO Symposium
(2d)
Ibrance Adds 15 Months of Progression-Free Survival in HR+, HER2+ Breast Cancer
(2d)
Risk Assessment Remains Vital for Patients Even After Cancer Diagnosis
(2d)
The Last Walk Down the Hall: Reflections Before Entering Cancer Survivorship
(2d)
Biotin, Lab Interference and Safer Options for Cancer-Related Hair Loss
(2d)
FDA Accepts Ivonescimab Application for EGFR Lung Cancer
(2d)
Study Identifies Why Some Breast Cancers Resist Enhertu Treatment
(2d)
Expert insights into Biomarker-Driven Care and Emerging Targets in GI Cancer
(3d)
Most Patients With HER2+ Breast Cancer Miss Standard Treatment, Study Shows
(3d)
Caregivers Often Overlook Their Own Health While Supporting Patients
(3d)
A Breast Cancer Survivor’s First Brush with Skin Cancer
(3d)
FDA Fast Tracks LBL-034 in Relapsed or Refractory Multiple Myeloma
(3d)
FDA Approves Larger Nelarabine Vial for Some Leukemias and Lymphomas
(3d)
The Emotional Side of Cancer Care Beyond Medical Treatment
(4d)
Managing Nutrition Changes in Patients With Gastrointestinal Cancers
(4d)
Grieving After Cancer: Advice for Those Grieving and Supporting Them
(4d)
Contract Pharma
Lilly to Build New Pennsylvania Manufacturing Facility
(2d)
Ardena Completes Divestment of Sweden Drug Substance Site to Nanologica
(2d)
Merz Therapeutics Taps Dan Staner as President, Region Europe
(2d)
Libris Innovations Taps Ramani Veranasi as CEO
(2d)
New Veeva Application Eliminates Paper, Streamlines Clinical Trial Data Flow
(3d)
Vetter to Build New Production Facility in Germany
(3d)
Opentrons Formally Announces James Atwood as CEO
(3d)
WuXi Biologics, Sinorda Biomedicine Partner to Advance SND006
(3d)
IQVIA to Share its DaaS+ Platform in Boehringer Ingelheim Collaboration
(3d)
Halozyme Acquires Surf Bio for up to $400M
(3d)
What FDA CRLs Reveal About EL
(3d)
Clinical Holds in Cell & Gene Therapies
(3d)
ADCs – Overcoming Analytical Challenges in Next-Gen Cancer Therapeutics
(3d)
Satellos Bioscience Taps Antoinette Paone as Chief Development Officer
(3d)
AstraZeneca to Invest $15 Billion in China Through 2030
(3d)
Elysium Therapeutics Raises $7.5M to Advance Opioid Overdose Reversal Tech
(4d)
Cellares Raises $257M to Industrialize Global Cell Therapy Manufacturing
(4d)
Fujirebio Unveils CSF Assay to Assist Alzheimer’s Research
(4d)
Veranova Taps Former Alcami Exec as Chief Quality Officer
(4d)
Five Decades of Partnership in Solid Oral Dose Manufacturing
(4d)
Pharma Times
CERo reports encouraging early data from phase 1 trial of CER‑1236
(3d)
ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
(3d)
Argo Biopharma doses first patient in phase 2b trial of BW‑20829
(4d)
Akari files new patent and advances second ADC targeting CEACAM5
(4d)
BioMed X launches kidney disease project in partnership with the government of Barbados
(5d)
Gedeon Richter UK takes over UK rights to cariprazine
(5d)
Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
(6d)
Corcept Therapeutics’ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer
(6d)
ErVimmune raises 17m euros in funding to develop cancer vaccine
(1w)
Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026
(1w)
Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
(2w)
Venner Shipley announces opening of new Bristol office
(2w)
AAX Biotech and Vascurie announce new neuro-oncology collaboration
(2w)
Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
(2w)
Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
(2w)
Ipsen announces new data on Dysport in neurological disease
(2w)
PMGroup Worldwide Ltd welcomes MAD World Summit
(3w)
Argenx receives review from FDA for VYVGART in seronegative gMG
(3w)
Nuclera extends Series C funding to advance antibody engineering
(3w)
Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
(3w)
Medcity News
Premise-Crossover Merger: Inside the $2B Push for a New Employer Health Model
(12h)
Is It Time to Change the Independent Dispute Resolution Process of the No Surprises Act?
(13h)
Medication Affordability Depends on Total Price Transparency
(13h)
2026 Is the Year of the Doctor-Patient Relationship
(14h)
Clinical Trial Holds Cast Doubt on Approval Chances of Regenxbio Gene Therapy for Rare Disease
(14h)
Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs
(2d)
4 Notable Health Tech Funding Announcements in January
(2d)
AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds
(2d)
Harnessing Clinical Expertise to Unlock Hospital Capacity
(2d)
Humanized AI: No Longer Optional for Digital Patient Engagement
(2d)
Health Tech Vendor Due Diligence: A HIPAA Security Guide for Medical Practices
(2d)
What Maven Clinic Hopes to Achieve With Its New Research Institute
(3d)
Epic vs. Health Gorilla: Inside the Battle Over Who Controls Your Medical Records
(3d)
What if Oprah Knew About Fractyl Health?
(3d)
Presbyopia Eye Drop From Startup Tenpoint Gets FDA Approval, Paving Way for $235M Financing
(3d)
Moving Beyond the Mega-Factory: Why the Future of Biomanufacturing is Agile, Distributed, and Resilient
(3d)
The 96-Hour Advantage: Why Early Diagnostic Accuracy Defines Clinical Outcomes
(3d)
The Growing Cost of Medical Bill Collection: How Healthcare Organizations Are Using New AI and Clinical Insights to Improve the Revenue Cycle Management Experience
(3d)
NOCD Launches Parent Brand Noto, Acquires PTSD Provider Rebound Health
(4d)
Climatic Emerges from Stealth With $10M to Build a Daily Lung Health Category
(4d)
Chemical & Engineering News
Jan. 30 Policy Watch: EPA re-ups plan to ditch animal testing for certain chemicals
(2d)
AstraZeneca signs $18.5 billion weight-loss-drug deal with Chinese firm
(2d)
Ancient Romans used human feces to make medicines
(2d)
‘ACS Nutrition Science’ publishes first issue
(2d)
US ultraprocessed food policy accelerates with bipartisan support
(2d)
Deluge of petrochemicals from China swamps other Asian countries
(3d)
Dow to cut 4,500 positions in new restructuring
(3d)
Chemistry in Pictures: Fight ice with starfish skeletons
(3d)
Podcast: Behind the scenes of the chaotic COP30
(3d)
‘Nature’ robot chemist paper corrected, but some questions remain unanswered
(3d)
Demand for ACS career services surged in 2025
(3d)
US vaccine guidance was evidence based—until now
(3d)
Siegfried to buy Noramco drug production business
(4d)
Google’s AlphaGenome predicts the function of a DNA sequence
(4d)
Obituary: Daniel Gravier
(4d)
How to put drug leads forgotten in the freezer back to work
(4d)
Jan. 27 Business Watch: Vioneo moves project to China; GSK to buy Rapt Therapeutics for $2.2 billion
(5d)
US air strikes are the latest blow to Venezuela’s decimated science infrastructure
(5d)
Obituary: Louis Brus
(5d)
Lithium helps reduce PFAS to reusable fluorine
(5d)
The Pharma Letter
The week in pharma: action, reaction and insight – week to January 30, 2026
(16h)
Kyowa Kirin to regain control of rocatinlimab
(1d)
Lundbeck presents new real-world data on Vyepti
(1d)
January 2026 batch of EMA/CHMP recommendations
(2d)
Strong quarter rounds off solid year for Regeneron
(2d)
David Berman to join Moderna executive team
(2d)
Recordati inks deal for Moderna drug
(2d)
AstraZeneca agrees obesity and T2D deal with CSPC
(2d)
Repertoire Immune inks deal with Lilly
(2d)
SpyGlass targets $150 million in IPO
(2d)
Johan Lund named PharmNovo board chair
(2d)
Samsung Bioepis reaches settlement for Eylea biosimilar
(2d)
BioMarin lines up $850m bond sale to finance Amicus takeover
(2d)
Chronic hepatitis D market set for steady growth as pipeline inches forward
(2d)
Agomab Therapeutics sets terms for Nasdaq IPO
(2d)
US regulator accepts Summit filing for ivonescimab combo
(2d)
Vetter Pharma to build new manufacturing site in Germany
(2d)
Bob Hoffman named chairman of the Association for Accessible Medicines
(2d)
MHRA updates guidance for GLP-1 prescribers and patients
(3d)
LifeArc Ventures hails four new investments and promises transformative 2026
(3d)
Targeted Oncology
Clinical Framing and Prognostic Assessment in Progressive Small Bowel Neuroendocrine Tumors
(15h)
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
(16h)
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
(1d)
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
(1d)
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
(2d)
Ancestry Outpaces Race in Predicting HNSCC Biology, Survival
(2d)
Neoadjuvant Pembrolizumab Achieves High pCR Rates in Desmoplastic Melanoma
(2d)
Lirafugratinib NDA Seeks FDA Approval in Cholangiocarcinoma
(2d)
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
(2d)
Selumetinib Granules Match Capsule Pharmacokinetics in Pediatric NF1-PN Study
(2d)
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
(2d)
Second-Line Therapy Selection and Disease Phenotype of cGVHD
(2d)
Case Presentation: From Acute GVHD to Steroid Dependence
(2d)
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
(3d)
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
(3d)
Amivantamab Regimen Maintains EGFR-Like Safety Profile in Metastatic CRC
(3d)
CTD402 Gains FDA Orphan Drug Designation in T-ALL and T-LBL
(3d)
Neoadjuvant Checkpoint Blockade Shows Efficacy, Safety in Cervical Cancer
(3d)
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
(3d)
Comparing Teclistamab Trial Designs for Early Relapsed Multiple Myeloma
(3d)
MedWatch
Employee representative leaves board of Novo Nordisk
(1d)
Eli Lilly plans to build a new factory in Pennsylvania for $3.5 billion
(1d)
Novo Nordisk’s director in China steps down
(2d)
Lundbeck shows strong performance again with best-selling migraine medication in new study
(2d)
Novo Nordisk nears EU approval for MASH drug
(2d)
Trump's online pharmacy is central to agreement with Novo Nordisk – launch now postponed
(2d)
Danish life science players on China train after confrontation with the US: "We must seek other avenues"
(2d)
AstraZeneca signs billion-dollar deal with Hong Kong-based CSPC for new slimming drugs
(2d)
Chinese biotech sector pressures Western rivals with rapid drug development
(2d)
Eli Lilly signs USD 1.84bn deal with Repertoire for new vaccines
(2d)
US prescriptions for Wegovy tablets continue to grow
(2d)
ALK gets EU recommendation for children's adrenaline nasal spray
(2d)
Trump says Eli Lilly is going to build six factories in the US
(2d)
Novo Nordisk gets green light for lawsuit against copycat for false advertising
(3d)
AstraZeneca to invest USD 15bn in China over four years
(3d)
Valneva's chikungunya vaccine under EU investigation after serious side effect
(3d)
French biotech Sensorion raises EUR 60m for gene therapy targeting hearing loss
(3d)
Novo Nordisk chairman warns of repeat insulin price war in obesity business
(3d)
Price negotiations could affect one-third of Lundbeck's US Rexulti sales
(3d)
This is how Lundbeck's price negotiations in the US will proceed
(3d)
In The Pipeline
A New LLM System for Synthesis Planning
(2d)
Rev Up The Viral Factories!
(3d)
Add Up Those Energies
(4d)
The Disastrous US Vaccine Landscape
(5d)
Microstructures All Around
(1w)
Bearing Down on a Placebo Effect
(2w)
What Makes A Drug
(2w)
Good Old Bewildering GPCRs
(2w)
Are There Accumulating Microplastics in Human Tissue or Not?
(2w)
Farewell to Dibromoethane
(3w)
mRNA Vaccines: What's the Adjuvant?
(3w)
A Clinical Trial Nightmare
(3w)
Those Darn Viruses
(4w)
Reversing Alzheimer's?
(4w)
Last Year, and the Year to Come
(4w)
Some Cold-Weather Holiday Food
(1mo)
A Mitochondrial Protein Hunt
(1mo)
Where Are They Now: Verge Genomics
(1mo)
Microbial Natural Products, Inventoried
(1mo)
Inhibitors and Degraders
(1mo)
Pharmaphorum
EMA looks into 'data integrity' issue with Amgen's Tavneos
(2d)
FDA starts review of Summit's VEGFxPD-1 bispecific
(2d)
Three more biotechs price their Nasdaq IPOs
(2d)
GLP-1 drugs linked to pancreatitis, gallbladder problems
(2d)
AZ deepens Chinese ties, signs $18.5bn CSPC obesity deal
(2d)
Tenpoint eyes presbyopia drug launch after FDA nod
(3d)
Digital musculoskeletal care firm Sword buys rival Kaia
(3d)
Otsuka preps for July decision on centanafadine for ADHD
(3d)
Halozyme diversifies in drug delivery with Surf Bio buy
(4d)
Eikon prices its IPO, seeking to raise $318m
(4d)
Lilly allies with gene-editing firm Seamless on hearing loss
(4d)
Boehringer drug scores in rare kidney disease FSGS
(4d)
CMS's Medicare price negotiations start round three
(4d)
UK biotech sees "strong finish" to 2025 financing
(4d)
Introducing the Sunday Times Tech 100: Life sciences part 3
(4d)
China clears its first drug for chronic hepatitis D
(5d)
Boehringer signs €1bn+ deal for Simcere IBD candidate
(5d)
Roche claims midstage win for obesity injectable
(5d)
Vaccination fall costs UK its measles elimination status
(5d)
Introducing the Sunday Times Tech 100: Life sciences part 2
(5d)
Drug Discovery Weekly
AZ expands China operations, agrees obesity deal with CSPC
(2d)
This week in Drug Discovery (26 – 30 January)
(2d)
European Commission approves RSV vaccine
(2d)
Gedeon Richter announces transfer of neuropsychiatry product
(2d)
TECregen appoints Dr Klaas Zuideveld as CEO
(2d)
Partnership set to advance organoid-based disease models
(2d)
New obesity drug may cause fewer side effects, results show
(3d)
Genetic markers drive breast cancer drug resistance, study shows
(3d)
Parkinson’s could be identified in the blood, study shows
(3d)
Webinar: Mapping disease trajectories with proteomics
(3d)
From plasma to prediction: Mapping disease trajectories with proteomics at unprecedented scale
(3d)
FDA clears IND application for melanoma treatment
(3d)
Allergies could be treated by therapeutic target, study finds
(3d)
Drug discovery and development in 2026
(3d)
New UK lab to accelerate cancer diagnostic solutions
(4d)
JPM 2026: Less talk and more action
(4d)
UK is Europe’s leading biotech market, BIA report shows
(4d)
Last chance to register: How can targeted proteomics accelerate drug discovery?
(4d)
DDW Highlights: 27 January 2026
(5d)
Novartis and SciNeuro collaborate on antibodies for Alzheimer’s
(5d)
HIT Consultant
MEDITECH Announces Passing of Founder Neil Pappalardo; Michelle O’Connor Named Interim Chair
(2d)
VA Allocates $1B for EHR Modernization as Part of Record FY26 NRM Spend
(2d)
Oracle May Cut 30k Jobs and Sell Cerner to Fund $156B OpenAI Deal
(2d)
Premise Health and Crossover Health Merge to Expand Advanced Primary Care
(2d)
Inside the $1.3B ”Smart Hospital”: How UCI Health and GW RhythmX Are Rewiring the Patient Experience
(2d)
Reimagining Care Delivery: 5 Imperatives for Operationalizing Enterprise-Wide RPM
(2d)
Beyond the Status Quo: 3 Core Pillars for Scaling a Private Practice in 2026
(2d)
AtlantiCare to Deploy Opmed.ai to Fix Surgical Scheduling Across Enterprise
(3d)
CB Insights Report: Digital Health Funding Hits $22.3B as 14 New Unicorns Emerge
(3d)
KLAS 2026 Rankings: Aledade and Guidehealth Named Top VBC Enablement Firms
(3d)
Medable Deploys ”Agentic AI” to Rescue Overwhelmed Investigators
(3d)
Beauregard Health Integrates Artera and DrFirst into MEDITECH Expanse for Unified Messaging
(3d)
Prenosis Secures $40M to Build the Precision Medicine Network for Critical Care
(3d)
Oracle Launches AI Platform to End the “Data Silo” Era in Pharma
(3d)
Indigo Raises $50M to Automate Medical Malpractice Insurance
(3d)
Silna Launches Industry’s First Predictive Document Intelligence to Proactively Clear Patients for Care
(3d)
Stop the Leak: How Missed Referrals Cost Health Systems Millions Annually
(3d)
Homecare Homebase 2026 Report: Medicare Advantage and AI Adoption Drive New Operational Strategy
(3d)
The Growing Importance of Custom Software in Modern Healthcare
(4d)
Sword Health Buys Kaia Health in $285M Deal to Expand AI Care Platform
(4d)
Insights: Pink Sheet
Public Complete Responses: US FDA Revised Corcept’s Letter To Fix Clarity, Not Facts
(2d)
Accelerated Approvals Perked Up While US FDA Excelled At Being Average In 2025
(2d)
Pink Sheet Podcast: Understanding US FDA’s CNPV Application Reviews
(2d)
Kygevvi & Kayshild Among Six Products To Get EMA Nod As Tavneos Faces Data Integrity Scrutiny
(2d)
EMA Backs Sanofi’s Rezurock After Initial Rejection On Advice From External Experts
(2d)
Japan’s Surprise Lower House Election May Bring Drug Pricing Reforms
(3d)
Innovation Appears Core Goal Of China’s Revised Drug Law
(3d)
US FDA Pushes Beyond Traditional Promotion, Challenges Microsoft Teams Background
(3d)
US Government Conditions DTC Drug Sales On Sponsors Putting No Conditions On Sales
(3d)
PDUFA VIII: Industry Proposes Releasing Redacted Action Packages For ‘All’ NDAs, BLAs
(3d)
Clinical Disclosure in 2026: How Misalignment Impacts Company Valuation and Litigation Risk
(3d)
Introducing Citeline’s Disclosure Alignment Risk Index: A Framework To Measure Trial Transparency
(3d)
New Irish Pharma Pacts Aim To Cut Delays For Innovative And Generic Drugs
(3d)
Predictable Yet Flexible: Sponsor-Driven Timelines Underpin UK’s New Clinical Trials Regime
(3d)
Medicare Negotiation List Spotlights Small Molecule Liability For Cancer Drugs
(4d)
Repeat Offenders: Neffy, Anktiva Promotions Draw Another US FDA Untitled Letter After Crackdown
(4d)
Market Developments Will Surpass Impact Of Pending PBM Reform Bill
(4d)
US Policy Shifts Push European SMEs To Rethink Investments And Launch Plans
(4d)
Swiss Fire Aftermath Highlights Urgent Need For European Antimicrobial Incentives
(4d)
Trump Looks To ‘Work Something Out’ After Korea Tariff Threat
(5d)
BioXconomy
AstraZeneca makes $18.5bn bet on CSPC’s weight loss drugs
(2d)
Inside Chiesi’s rare disease partnership playbook
(2d)
Finding the opportunity in challenging times: Europe’s biotech landscape
(3d)
AbbVie strikes $100bn deal with Trump administration to boost US drug access and manufacturing
(4d)
Immuno Cure’s DNA-based HIV vaccine trial begins in China
(4d)
mRNA-antibody combination treatment keeps melanoma at bay, study finds
(4d)
Moderna does not ‘foresee investing’ in Phase III trials, says CEO
(4d)
Merck reportedly pauses acquisition talks with Revolution Meds amid valuation disputes
(4d)
Babies as ‘guinea pigs’: A vaccine trial in Guinea-Bissau comes under intense scrutiny
(5d)
Financial considerations in entering the Asian biotech market
(5d)
EMA report calls for ethical AI guardrails in clinical trials while fostering innovation
(6d)
Medicaid processing continues to challenge the pharmaceutical industry
(6d)
Worldwide Clinical Trials acquires Catalyst Clinical Research to boost oncology capabilities
(6d)
Financial acumen needed to thrive in Europe
(6d)
Biotech firms tap new CFOs in January leadership shuffle
(6d)
Shionogi expands stake in ViiV Healthcare following Pfizer’s exit, GSK retains majority share
(6d)
Corxel advances oral GLP-1 therapy with $287m investment
(6d)
Pharma leaders stress cross-functional collaboration as key to gross-to-net financial success
(1w)
ADCs boost effectiveness of radiotherapy, say University of Washington researchers
(1w)
Mendra raises $82M Series A for rare disease drugs
(1w)
BioCentury
2026 Cardiovascular Catalysts: Lp(a) on the Horizon
(2d)
2026 Catalysts: Breakthrough progress in renal disease
(2d)
Eikon aims high for NASDAQ listing: Public Equity Report
(2d)
Survey results: What sponsors say is slowing cancer trials — and what’s helping
(2d)
AZ signals all-in on obesity via CSPC deal for $1.2B up front
(2d)
Obesity catalysts in 2026
(3d)
2026 Obesity Catalysts: Launches, readouts and challengers
(3d)
Venture bets, dealmaking key features of AZ’s China strategy
(3d)
Manufacturing companies Cellares, Antheia among the week’s fundings: Venture Report
(3d)
2026 Catalysts: The rise of RNAi
(4d)
Roche’s GLP-1/GIP entering late-stage with competitive efficacy
(4d)
Changes in Cardiff’s C-suite amid late-stage push for cancer candidate
(4d)
China’s orphan drug exclusivity could bolster market, incentivize development
(4d)
Broadening T cell control in atopic dermatitis
(5d)
2026 Catalysts: Psychiatry, epilepsy and neurodegeneration
(5d)
2026 Catalysts: Psychiatry, epilepsy and neurodegeneration in focus
(5d)
Miles Gerson, Sofia Guerra among VCs landing new roles
(6d)
Speeding China’s innovation. Plus: 2026’s neuro catalysts — a BioCentury podcast
(6d)
Revolution’s shares dip with report of Merck walking away: Deals Report
(6d)
New rules add rigor while fueling China’s gene and cell therapy engine
(6d)
SCRIP
PharmAbcine Founder Calls For Protections For Korean Biotechs After Delisting
(42m)
Quick Listen: Scrip’s Five Must-Know Things
(1h)
Sun On ‘Disciplined’ M&A Approach, Day 1 Launch Readiness For Semaglutide In India
(4h)
Finance Watch: SPACs Attempt A Comeback As IPO Market Shows Signs Of Life
(2d)
Quince Therapeutics’ Fruit Spoils As Phase III A-T Study Falls To Ground
(2d)
Amgen Returns Eczema Drug To Kyowa Kirin On Marketability Doubts
(2d)
Roche Awaits Key Readouts In 2026 – Including Its Potential Biggest Ever Drug
(2d)
$10.7bn India OTC Opportunity Awaits Pharma, Will Regulatory Reform Flow?
(2d)
Sanofi’s Hudson Cuts Through Noise To Champion Vaccines
(2d)
Executives On The Move: Three CEOs And Four CFOs Among This Week’s Changes
(2d)
Positive Long-Term China Safety Data For Ascletis’s Oral Acne Contender
(2d)
AstraZeneca Bets $18.5bn On CSPC’s Sustained-Release And AI Peptide Platforms In Weight Management
(3d)
Takeda Touts Trinity Of Rusfertide, Oveporexton, Zasocitinib In Growth Strategy
(3d)
Asia Deal Watch: Kanghua Will Move Into Vaccines By Purchasing Chinese Peer NanoRibo
(3d)
As Novo Nordisk Doubles Down In Obesity And Diabetes, What Exactly Is It Looking For?
(3d)
Repertoire Adds Lilly To Its Set Of ‘A-List’ Partners
(3d)
Sanofi CEO Calls For Patience And Faith In Pipeline Ahead Of Dupixent Expiry
(3d)
Roche CEO To Switzerland: You Need To Adapt To Pharma’s New World Order
(3d)
Quotables: Pharma Leaders On The Month’s Hot Topics
(3d)
CalciMedica Shares Plunge After Discontinuing Phase II AKI Study
(3d)